Forty Seven
General Information | |
Business: |
We are a clinical-stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. We founded Forty Seven based on the insight that blocking CD47, a key signaling molecule that is overexpressed on cancer cells, renders tumors susceptible to macrophages. By harnessing macrophages, we believe that our lead product candidate, 5F9, dosed as a monotherapy or in combination with marketed cancer therapies, can transform the treatment of cancer. 5F9 has demonstrated promising activity in six Phase 1b/2 clinical trials in which we have treated over 190 relapsed or refractory cancer patients with solid or hematologic tumors. We hold worldwide rights to all of our product candidates.
|
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 46 |
Founded: | 2014 |
Contact Information | |
Address | 1490 O’Brien Drive, Suite A, Menlo Park, CA 94025, US |
Phone Number | (650) 352-4150. |
Web Address | http://www.fortyseveninc.com |
View Prospectus: | Forty Seven |
Financial Information | |
Market Cap | $479.4mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-48.8 mil (last 12 months) |
IPO Profile | |
Symbol | FTSV |
Exchange | NASDAQ |
Shares (millions): | 7.0 |
Price range | $16.00 - $16.00 |
Est. $ Volume | $112.6 mil |
Manager / Joint Managers | Morgan Stanley/ Credit Suisse |
CO-Managers | Canaccord Genuity/ BTIG/ Oppenheimer |
Expected To Trade: | 6/28/2018 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |